z-logo
open-access-imgOpen Access
Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis
Author(s) -
Sangun Lee,
Melanie Ginese,
Gillian Beamer,
Hillary Danz,
Donald Girouard,
Susan Chapman-Bonofiglio,
Minhee Lee,
Matthew A. Hulverson,
Ryan Choi,
Grant R. Whitman,
Kayode K. Ojo,
Samuel L.M. Arnold,
Wesley C. Van Voorhis,
Saul Tzipori
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00147-18
Subject(s) - cryptosporidium , diarrhea , cryptosporidium parvum , microbiology and biotechnology , acute diarrhea , biology , medicine , immunology , virology , gastroenterology , feces
Recent reports highlighting the global significance of cryptosporidiosis among children have renewed efforts to develop control measures. We evaluated the efficacy of bumped kinase inhibitor (BKI) 1369 in the gnotobiotic piglet model of acute diarrhea caused byCryptosporidium hominis , the species responsible for most human cases. Five-day treatment with BKI 1369 reduced signs of disease early during treatment compared to those of untreated animals. Piglets treated with BKI 1369 exhibited significant reductions of oocyst excretion, mucosal colonization byC. hominis , and mucosal lesions, which resulted in considerable symptomatic improvement. BKI 1369 reduced the parasite burden and disease severity in the gnotobiotic pig model. Together these data suggest that a BKI-mediated therapeutic may be an effective treatment against cryptosporidiosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom